CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Cellectis S.A.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 20, 2026
$0.93−0.11 (-11.01%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
9.4%
9M of 100M shares
Institutional holders
27
3 new, 8 sold out
Net institutional buying
-1M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Long Focus Capital Management, LLC | 4,487,293 | 6.30% | 13G (passive) amendment | Dec 31, 2023 |
| AstraZeneca PLC | 44,000,000 | 44.00% | 13D (active) amendment | Jan 23, 2025 |
| Caisse des Depots | 10,599,440 | 11.10% | 13D (active) amendment | Dec 3, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CLLS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| B Group, Inc. | 3,281,501 | 3.27% | $9.84M | – | 4.62% |
| Long Focus Capital Management, LLC | 2,741,853 | 2.73% | $8.23M | −2,245 | 0.21% |
| UBS Asset Management Americas Inc | 2,644,881 | 2.64% | $7.93M | −533,739 | 0.00% |
| Nomura Asset Management International Inc. | 226,875 | 0.23% | $681.00K | – | 0.00% |
| BlackRock, Inc. | 225,444 | 0.22% | $676.33K | −116,079 | 0.00% |
| Morgan Stanley | 85,455 | 0.09% | $256.37K | −1,321 | 0.00% |
| LPL Financial LLC | 84,415 | 0.08% | $253.25K | +70 | 0.00% |
| Susquehanna International Group, Llp | 50,453 | 0.05% | $151.36K | −15,489 | 0.00% |
| Bnp Paribas Arbitrage, Snc | 40,100 | 0.04% | $120.30K | −900 | 0.00% |
| UBS Group AG | 33,926 | 0.03% | $101.78K | +4,152 | 0.00% |
| Delaney Dennis R | 24,000 | 0.02% | $72.00K | – | 0.02% |
| Rhumbline Advisers | 14,328 | 0.01% | $42.98K | −757 | 0.00% |
| XTX Topco Ltd | 12,282 | 0.01% | $36.85K | −3,987 | 0.00% |
| Harbour Investments, Inc. | 4,500 | 0.00% | $13.50K | – | 0.00% |
| National Bank Of Canada /Fi/ | 3,600 | 0.00% | $10.80K | – | 0.00% |
| Wells Fargo & Company/Mn | 3,150 | 0.00% | $9.45K | – | 0.00% |
| Royal Bank of Canada | 1,558 | 0.00% | $5.00K | New | 0.00% |
| Atlantic Union Bankshares Corp | 1,500 | 0.00% | $4.50K | – | 0.00% |
| Allworth Financial LP | 500 | 0.00% | $1.50K | – | 0.00% |
| POM Investment Strategies, LLC | 495 | 0.00% | $1.49K | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 27 | 9M | 9.4% | 3 / 2 | 9 / 8 | 0M | 1M |
| Q1 2026 | 32 | 10M | 10.2% | 4 / 3 | 14 / 5 | 0M | 0M |
| Q4 2025 | 34 | 11M | 10.5% | 13 / 6 | 5 / 6 | 4M | 2M |
| Q3 2025 | 28 | 8M | 8.3% | 7 / 6 | 6 / 3 | 0M | 4M |
| Q2 2025 | 24 | 12M | 11.7% | 3 / 5 | 8 / 6 | 0M | 2M |
| Q1 2025 | 27 | 14M | 13.6% | 3 / 6 | 8 / 5 | 4M | 3M |
| Q4 2024 | 29 | 13M | 12.7% | 6 / 6 | 6 / 4 | 4M | 1M |
| Q3 2024 | 27 | 10M | 9.7% | 3 / 5 | 5 / 2 | 0M | 0M |
| Q2 2024 | 27 | 10M | 9.7% | 4 / 3 | 7 / 7 | 2M | 0M |
| Q1 2024 | 31 | 10M | 10.0% | 3 / 9 | 5 / 5 | 0M | 0M |
| Q4 2023 | 34 | 10M | 9.9% | 9 / 7 | 8 / 6 | 0M | 2M |
| Q3 2023 | 31 | 11M | 11.4% | 2 / 8 | 6 / 7 | 0M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of CLLS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Nomura Healthcare Fund | 226,875 | 0.23% | $680.63K | 0.09% | Jun 30, 2026 |
| iShares Biotechnology ETF | 223,114 | 0.22% | $669.34K | 0.01% | Jun 30, 2026 |